Compare · NVO vs ZLAB
NVO vs ZLAB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zai Lab Limited (ZLAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZLAB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 102.7x ZLAB ($1.87B).
- Over the past year, NVO is down 43.1% and ZLAB is down 56.1% - NVO leads by 13.0 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 5 for ZLAB).
- NVO has more recent analyst coverage (25 ratings vs 11 for ZLAB).
- Company
- Novo Nordisk A/S
- Zai Lab Limited
- Price
- $42.94-1.84%
- $16.63-4.23%
- Market cap
- $191.82B
- $1.87B
- 1M return
- -6.14%
- -20.79%
- 1Y return
- -43.10%
- -56.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Zai Lab Limited
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrödinger, Inc.; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest ZLAB
- Chairperson & CEO Du Ying gifted 107,700 units of American Depositary Shares, decreasing direct ownership by 9% to 1,158,583 units (SEC Form 4)
- Zai Lab Announces Changes to Senior Leadership Team
- Zai Lab Limited filed SEC Form 8-K: Leadership Update
- Chairperson & CEO Du Ying exercised 261,092 units of American Depositary Shares at a strike of $1.74 and covered exercise/tax liability with 117,435 units of American Depositary Shares, increasing direct ownership by 13% to 1,266,283 units (SEC Form 4)
- Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $1,986,875 worth of American Depositary Shares (100,000 units at $19.87) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Edmondson Frazor Titus Iii sold $71,008 worth of American Depositary Shares (3,517 units at $20.19) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 19,849 units (SEC Form 4)
- Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $2,003,044 worth of American Depositary Shares (100,000 units at $20.03) as part of a pre-agreed trading plan (SEC Form 4)
- Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
- SEC Form 10-Q filed by Zai Lab Limited
- Zai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits